Atea Pharmaceuticals Inc (AVIR)vsAstraZeneca PLC (AZN)
AVIR
Atea Pharmaceuticals Inc
$5.51
+1.47%
HEALTHCARE · Cap: $440.95M
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 30465% more annual revenue ($58.74B vs $192.18M). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AVIR
Buy54
out of 100
Grade: C-
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+56.7%
Fair Value
$10.30
Current Price
$5.51
$4.79 discount
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 295.2% year-over-year
Earnings expanding 264.1% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AVIR
The strongest argument for AVIR centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 295.2% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : AVIR
The primary concerns for AVIR are Market Cap, Profit Margin, Operating Margin.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
AVIR profiles as a hypergrowth stock while AZN is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
AVIR is growing revenue faster at 295.2% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 54/100), backed by strong 17.4% margins. AVIR offers better value entry with a 56.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Atea Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?